Galectin Therapeutics
GALT
65 hedge funds and large institutions have $58.6M invested in Galectin Therapeutics in 2014 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 13 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
18% more funds holding
Funds holding: 55 → 65 (+10)
9% more capital invested
Capital invested by funds: $53.9M → $58.6M (+$4.73M)
45% less call options, than puts
Call options by funds: $1.92M | Put options by funds: $3.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.63M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.88M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.43M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.12M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$824K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$3.06M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.49M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$2.48M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.04M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.78M |
GALT Hedge Fund Activity: Q2 2014 in Review
65 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2014, worth a combined $58.6M — up 8.8% from $53.9M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new GALT positions and 13 closed out — a net gain of 10 holders — while 22 added to existing stakes and 12 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $5.63M. The largest seller was Mangrove Partners, exiting entirely with an estimated $3.06M sold.
- 65 institutional investors held Galectin Therapeutics (GALT) as of Q2 2014, up from 55 in Q1 2014.
- Funds reported $58.6M of Galectin Therapeutics stock for Q2 2014, up 8.8% quarter-over-quarter.
- 23 funds opened new Galectin Therapeutics positions in Q2 2014 and 13 closed out, a net change of +10 holders.
- The largest Galectin Therapeutics buyer in Q2 2014 was Cormorant Asset Management, an estimated $5.63M added.
- The largest Galectin Therapeutics seller in Q2 2014 was Mangrove Partners, an estimated $3.06M sold.
Based on aggregated 13F filings for Q2 2014.